Members of the TET family of proteins help protect against cancer by regulating the chemical state of DNA —and thus turning growth-promoting genes on or off.

The latest findings reported by researchers at La Jolla Institute for Allergy and Immunology illustrate just how important TET proteins are in controlling cell proliferation and cell fate.

For the study, published in Nature Immunology, Anjana Rao, PhD, a professor at the La Jolla Institute, genetically engineered mice to lack both TET2 and TET3 in T cells.

The mice developed a lethal disease resembling lymphoma within weeks of birth, their spleens and livers bloated with iNKT cells, a normally rare kind of T cell.

This finding recapitulated the features of many human blood cancers, including those involving T cells, in which TET2 is often mutated or lost.

"We knew that TET proteins were involved in human cancer but we didn't know how they regulated T cell development," says Angeliki Tsagaratou, Ph.D., an instructor in the Rao lab and the study's first author. "In the new study we saw huge increases in the proliferation of the special iNKT cells in TET2/3 mutant mice. Once growth control was lost, those cells underwent the kind of malignant transformation that gives rise to T cell lymphoma in humans." The results demonstrate how TET proteins serve as anti-cancer factors called tumour suppressors and suggest ways to block malignancy in cancers marked by TET mutations.

Members of the TET family of enzymes help rewrite the epigenome, the regulatory layer of chemical modifications that sits atop the genome and helps determine gene activity without changing the letters of DNA.

In addition to the four letters or bases in DNA – A, C, G and T – there is a “fifth base” with a very important role.

This base is formed from the DNA base cytosine (C) by addition of a methyl group, and so is called mC (m for methyl).

The levels of mC are altered in cancer cells and during the development of embryos.

However, until the discovery of TET proteins in 2009 in the laboratory of Rao, then at Harvard Medical School, it was not known how mC could be converted back to regain C. Dr. Rao’s team showed that TET proteins were able to convert 5mC to a sixth base, known as 5hmC.

5hmC is indirectly converted back to C, thus restoring the status quo.

DNA modifications of this type in part govern how compressed and "expressible" a strand is: in general, DNA methylation coils up genes to silence them, while less methylated DNA strands, or strands that possess 5hmC, are more accessible and more likely to be expressed, which means they are directing the synthesis of a particular protein. "When TET proteins are lost, iNKT cells that lack them apparently become trapped in an immature, highly proliferative state," explains Tsagaratou. "Unlike normal cells, they can't switch off growth-promoting genes: they just keep dividing."

DNA sequencing followed by bioinformatic data-crunching revealed the kinds of abnormal DNA methylation patterns typically seen after TET protein loss.

That suggested that improper DNA modifications in the TET2/3 mutant T cells allowed unchecked expression of cancer- and inflammation-associated genes.

Edahí González-Avalos, one of the two second authors of the study, conducted most of that analysis.

"Without computer analysis of sequencing results, we would not have been able to determine relationships between DNA methylation, how accessible regions of the genome were, global gene expression, or the emergence of cancer cells," says González-Avalos, a graduate student in UCSD's Bioinformatics Graduate Program. "Without computational tools, this study could have taken many, many years!"

A critical test reported in the paper demonstrates how insidious even a few perpetually immature iNKT cells can be.

In it, the team transferred a small number of iNKT cells lacking Tet2/3 from mutant mice into adult mice with a robust immune system.

But even those mice soon developed lymphoproliferative disease as lethal as that seen in TET2/3 mutant mice.

"We weren't expecting this," says Tsagaratou. "When we transferred mutant cells we thought healthy mice would control their expansion. But in three months mutant cells took over the mouse's immune system and rapidly gave rise to tumors." The lesson of this story? That a functional immune system is no defense against malignancy once deregulated, pro-inflammatory iNKT cells gain a foothold.

In a 2015 Nature Communications paper, Rao, who heads LJI's Division of Signaling and Gene Expression, reported that TET2/3 mutations caused myeloid disease resembling acute myeloid leukaemia in mice.

The new study extends these findings to a different class of haematological cancers, namely lymphoid cancer, which is caused by abnormal activity of immune T or B cells.

"Right now we don't know how TET mutations specifically contribute to either T cell lymphomas or leukaemias. But we think these mutations are early events in both," says Tsagaratou. Thus the search is on is to discover additional cancer-causing genes "downstream" of TET mutations that drive uncontrolled cell division in either context. "Identification of additional factors would give us a broad idea of all steps in pathway and provide multiple targets to hit."

Source: La Jolla Institute for Allergy and Immunology